one dollar, page-16

The scope of the Exclusivity List allows Unilife to commence formal discussions with other pharmaceutical companies relating to the potential use of the Unifill(TM) syringe within a number of significant therapeutic classes that fall outside of those areas retained by sanofi-aventis.
Unilife and sanofi-aventis Agree to Exclusivity List for Unifill(TM) Ready-to-Fill Syringe
3 march 2010
These companies are competitors with Unilife across a number of fields not just RTF
It?s a similar case to stason not wanting to pay kindly for syringes when kindly is competing with them

During the Period of Exclusivity, sanofi-aventis may also nominate additional therapeutic sub-groups to be placed onto the Exclusivity List should the Company not have already signed a commercial arrangement within this sub-group with a third party. Before an additional therapeutic class can be added to the Exclusivity List, both parties will need to be reasonably satisfied that a target drug suitable for use with the Unifill(TM) syringe is likely to generate a commercial order.

Supply to Other Pharmaceutical Companies: Unilife has retained the right to enter into agreements with other pharmaceutical companies which may seek to use the RTFS with injectable drug products marketed in Unilife Therapeutic Drug Classes. Sanofi-aventis will receive a 5% royalty on revenue generated from sales of the RTFS to other pharmaceutical companies. Royalty payments to sanofi-aventis will cease when Unilife's total revenues from these other pharmaceutical companies reaches